PMC4738166

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Mothers who received PREPP reported significantly fewer bouts of infant fussing and crying at 6 weeks postpartum than mothers in the ETAU group.

Effect: improvement; F (1, 28) = 5.68

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84